Array ( [0] => Array ( [acf_fc_layout] => text_editor_block [text_editor] => Open Pledge from Global Manufacturers of Generic Medicines against COVID-19 In November 2020, a united group 18 companies representing a large portion of the world’s generic pharmaceutical manufacturers pledged to work together via the Medicines Patent Pool (MPP) to accelerate access to hundreds of millions of doses of new COVID-19 interventions for low- and middle-income countries (LMICs). Today, this number has grown to 25 and the open pledge continues to call on other leading players in the generic medicines landscape to join the generic manufacturers in this united effort and sign this pledge so that we can work shoulder to shoulder to end this pandemic. As a united group of leading pharmaceutical manufacturing companies, suppliers and distributors from around the world providing treatments to millions, most of whom live in LMICs, we come together, through this signed pledge to support the fight against COVID-19. We affirm our joint engagement and offer our capacity to develop and supply COVID-19 treatments – re-purposed, new, small molecules and biologics – to those in need. One thread that connects us, the signees of this pledge, is our commitment to the fight against COVID-19 and our willingness to work with the UN-backed MPP in ensuring that no one is left behind. MPP’s model, with its transparency, non-exclusivity and proven track record, has set the gold standard for public health voluntary licensing. Access the press release The task is mammoth, the demand is global. The collective gets stronger with each generic manufacturer, supplier and distributor joining the effort. To join the pledge and offer your production and/or supply capacity, click “Join the pledge” below. JOIN THE PLEDGE To show your support for the effort in ensuring that LMICs are not left behind as COVID-19 treatments become available, click “Support the pledge” below. SUPPORT THE PLEDGE Note: Joining or supporting the pledge is in no way legally binding. It simply affirms your intent and support in ensuring rapid access to treatments to those in need wherever they live in the world through the voluntary licensing mechanism of MPP. Signees: [text_editor_styles] => Array ( [alignment] => left [text_colour_font] => text-default [background_colour] => false [background_image] => Array ( [ID] => 7709 [id] => 7709 [title] => pledge_logo_blue_transparent_resized [filename] => pledge_logo_blue_transparent_resized-e1605108258357.png [filesize] => 5831 [url] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357.png [link] => https://stage2.mpp.acw.website/covid-19/mpp_global_manufacturers_open_pledge/pledge_logo_blue_transparent_resized [alt] => [author] => 14 [description] => [caption] => [name] => pledge_logo_blue_transparent_resized [status] => inherit [uploaded_to] => 7697 [date] => 2020-11-11 15:00:07 [modified] => 2020-11-11 15:00:07 [menu_order] => 0 [mime_type] => image/png [type] => image [subtype] => png [icon] => https://stage2.mpp.acw.website/wordpress/wp-includes/images/media/default.png [width] => 1042 [height] => 1042 [sizes] => Array ( [thumbnail] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357-150x150.png [thumbnail-width] => 150 [thumbnail-height] => 150 [medium] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357-300x300.png [medium-width] => 300 [medium-height] => 300 [medium_large] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357-768x768.png [medium_large-width] => 768 [medium_large-height] => 768 [large] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357-1024x1024.png [large-width] => 1024 [large-height] => 1024 [1536x1536] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357.png [1536x1536-width] => 1042 [1536x1536-height] => 1042 [2048x2048] => https://stage2.mpp.acw.website/uploads/2020/11/pledge_logo_blue_transparent_resized-e1605108258357.png [2048x2048-width] => 1042 [2048x2048-height] => 1042 ) ) [background_image_style] => center / cover no-repeat [overlay_colour] => false ) ) [1] => Array ( [acf_fc_layout] => accordion [expanding_section] => Array ( [0] => Array ( [title] => Endorsements [content] => “Working with MPP over the years has enabled Adcock Ingram to provide access to live saving medication to those in need in South Africa and its surrounds.” “Associating with MPP has put us at the forefront of improving the accessibility and affordability of HIV medication. Our values and vision are closely aligned and they have continuously inspired us to do more for this cause.” – Arene Life Sciences “We are committed to the cause of providing increased access to affordable high quality life saving medicines in low- and middle-income countries in several therapy areas including HIV. We have worked successfully with MPP over the years to this effect and will continue our fight through these valuable partnerships.” – Aurobindo “MPP is committed to fighting health disparity through its unique strategy and we are proud to be a part of this network with the common goal of ensuring access to medicines for all.” – Beximco “The very foundation of Cadila Pharmaceuticals is synonymous with quality and affordability of life-saving medicines. Our association with the MPP further strengthens our resolve to extend high-quality novel drugs to the last mile. Our expertise spans all major therapy areas and first-in-the-world innovations. Our immunomodulatory drug Sepsivac, used in gram negative sepsis, has been found to help in boosting innate immune response and has shown promising results in management of COVID 19 and also in increasing resistance against the development of COVID-19.” “Medicines Patent Pool has led Paths of pharmaceutical products into People’s lives.” – Celltrion “Our endeavour to ensure equitable access to quality and affordable healthcare is entrenched in our humanitarian purpose of ‘Caring for Life’ that has driven our efforts in India and globally over the past 85 years. Our partnership with MPP has helped us in providing access to life-saving drugs for HIV and other therapies.” – Cipla “The capacity and capability of global leading generics pharmaceutical manufacturers have been better utilized with MPP’s coordination to make the life-saving HIV and hepatitis C medicines available and affordable in LMICs. We Desano feel proud to be part of this.” “MPP make life-saving medicines in low- and middle-income countries affordable, we feel great honour to be a member of the team, contributing our capacity and delivery.” – Jiangxi Dongbang Pharmaceutical “We believe that accelerating access to good health requires – developing medicines where affordable alternatives don’t exist, working with all stakeholders in the healthcare systems and ensuring adequate availability of medicines. Aligned with our belief, ‘Good Health Can’t Wait’, we are committed to addressing unmet patient needs along with MPP.” – Dr. Reddy’s “We are privileged to have partnered with MPP for the past decade which has led to creating a larger access to life-saving medicines across the globe; not only with HIV but for other therapies as well.” – Hetero “Our company mission is contributing to the healthcare by supporting the improvement of medicine availability and affordability. It is great to work with MPP and Licensors to meet the urgent need of patients by providing more affordable medicines.” – Langhua Pharma “MPP is spearheading an initiative that is so imperative for the developing countries around the world to have access to affordable, lifesaving medicines. We acknowledge the sincere efforts of Medicines Patent Pool to work alongside generic manufacturers to accelerate the development of affordable medications to LMICs.” – Lupin “Access is at the core of all work undertaken by the team at MPP. This has helped in close cooperation between pharma and generics and has ensured that newer and safer medicines reach people across LMICs.” – Macleods “We at Mangalam Drugs & Organics Ltd. take great pride in being associated with MPP that is striving relentlessly to provide rapid access to effective healthcare across the globe. Having partnered with this organisation has enabled us to envision beyond the ordinary. We look forward to continued alliance with them and to be able to build on each other’s strengths for sustainable benefits to those who have limited reach.” “At Micro Labs we duly appreciate the initiative taken by the team at MPP. MPP’s efforts rightly opportune generic players to leverage their capabilities in reaching out to more patient population with quality and affordable medicines.” “We believe the collaboration with MPP on expanding treatment access to affordable Hepatitis drugs has made a huge impact in many countries. It has been particularly satisfying to be part of the solution to tackle Hepatitis pandemic.” – Natco “Our Stridian organizational values of Integrity, Collaboration and Efficiency resonate very well with those of the Medicines Patent Pool. Over the years, our partnership has promoted inclusivity, and worked towards making life-saving drugs affordable and accessible to large parts of the lower and middle income countries, thereby making a significant difference to public health.” – Strides Pharma “The partnership with MPP & its licensing model has enabled supply of critical life-saving medicines to patients in low- & middle-income countries around the world.” – Sun Pharma “Our association with MPP has strengthened our resolve in combating the scourge of hepatitis C. The inclusion of Daclatasvir to our anti-hep C portfolio has helped us extend Daclatasvir as a highly affordable treatment option to thousands of patients, suffering from hepatitis C, thereby improving both, their access to treatment and clinical outcomes.” – Zydus Cadila ) ) ) [2] => Array ( [acf_fc_layout] => text_editor_block [text_editor] => Press [text_editor_styles] => Array ( [alignment] => left [text_colour_font] => text-default [background_colour] => false [background_image] => [background_image_style] => center / cover no-repeat [overlay_colour] => false ) ) [3] => Array ( [acf_fc_layout] => post_grid [show_latest_posts] => [post_grid_layout] => rectangular [background_colour] => bg-pale-yellow [posts_per_row] => 2 [posts_to_display_in_grid] => Array ( [0] => WP_Post Object ( [ID] => 7715 [post_author] => 14 [post_date] => 2020-11-12 00:01:53 [post_date_gmt] => 2020-11-12 00:01:53 [post_content] => 18 companies join the effort by Medicines Patent Pool to accelerate global access to effective COVID-19 treatments via a pool for voluntary product licences Geneva – With COVID-19 infections surging worldwide, a united group of 18 companies representing a large portion of the world’s generic pharmaceutical manufacturers pledged to work together to accelerate access to hundreds of millions of doses of new interventions for low- and middle-income countries (LMICs) via the non-profit Medicines Patent Pool (MPP). “This unprecedented cooperation from companies that are typically competitors represents a breakthrough in our efforts to level the playing field for access to drugs that will be crucial to controlling and defeating this pandemic,” said Charles Gore, Executive Director of MPP. “These are companies with an excellent track record of working with originators to ensure generic versions of their innovations meet high standards for quality – while answering the need for more affordable, accessible therapies.” Gore noted that collectively the 18 companies joining the pledge have the capacity to deliver substantial amounts of conventional drugs, technically known as “small molecules” in industry parlance, and an increasing ability to produce more molecules known as biologics. Biologics include monoclonal antibodies targeting COVID-19 that have shown promise as potential ways to either treat or prevent infections—but cost and manufacturing capacity pose substantial barriers to deploying them globally. Gore said he hopes the pledge by such a respected group of generic industry players to produce large volumes of high-quality COVID-19 treatments will encourage firms now developing either new or re-purposed therapies to negotiate agreements allowing rapid access to those in need. This can be either through licensing of their intellectual property, or where licences are not needed, facilitating ways to scale up manufacturing capacity to meet the high demands. “We welcome this pioneering collaboration and encourage others to join. Making sure there is enough supply capacity of potential game-changing treatments for COVID-19 is critical to ensure equitable access in low- and middle-income countries. Using the proven MPP model to ensure access to effective and affordable health solutions not only makes sense in this COVID-19 emergency but is the right thing to do,” said Dr Philippe Duneton, Executive Director of Unitaid. The companies joining the effort are connected by their past work with MPP, an organisation created in 2010 by the global health initiative Unitaid to negotiate patent licence agreements with pharmaceutical companies that are placed in a pool to make them more easily accessible for generic manufacturers. Thus far, agreements negotiated by MPP with companies such as ViiV Healthcare, Bristol Myers Squibb and AbbVie have allowed generic producers to provide over 15 billion doses of HIV and hepatitis C medicines to low- and middle-income countries. Despite the logistical challenges of the pandemic, in the first six months of 2020 alone, MPP’s licensees have delivered three billion doses. Combining the capacity of generic firms with patent agreements negotiated by MPP is increasingly viewed as an important addition to efforts to ensure COVID-19 interventions are available outside of the world’s wealthiest countries. For example, the European Union has called for “maximizing accessibility” to the fruits of COVID-19 R&D via initiatives that include “the pooling of technology to any UN-endorsed patent pool, such as the Medicines Patent Pool.” The G20 joint Finance and Health Ministers’ statement in September, also cited voluntary licensing of intellectual property as one of the key tools in the COVID-19 response. Several signatories have stepped forward to underscore the importance of the pledge: “Working with MPP over the years has enabled Adcock Ingram to provide access to live saving medication to those in need in South Africa and its surrounds.” "Associating with MPP has put us at the forefront of improving the accessibility and affordability of HIV medication. Our values and vision are closely aligned and they have continuously inspired us to do more for this cause." – Arene Life Sciences "We are committed to the cause of providing increased access to affordable high quality life saving medicines in low- and middle-income countries in several therapy areas including HIV. We have worked successfully with MPP over the years to this effect and will continue our fight through these valuable partnerships." – Aurobindo “MPP is committed to fighting health disparity through its unique strategy and we are proud to be a part of this network with the common goal of ensuring access to medicines for all.” – Beximco “Medicines Patent Pool has led Paths of pharmaceutical products into People's lives.” – Celltrion "The capacity and capability of global leading generics pharmaceutical manufacturers have been better utilized with MPP’s coordination to make the life-saving HIV and hepatitis C medicines available and affordable in LMICs. We Desano feel proud to be part of this." “We are privileged to have partnered with MPP for the past decade which has led to creating a larger access to life-saving medicines across the globe; not only with HIV but for other therapies as well.” – Hetero "MPP is spearheading an initiative that is so imperative for the developing countries around the world to have access to affordable, lifesaving medicines. We acknowledge the sincere efforts of Medicines Patent Pool to work alongside generic manufacturers to accelerate the development of affordable medications to LMICs." – Lupin "Our company mission is contributing to the healthcare by supporting the improvement of medicine availability and affordability. It is great to work with MPP and Licensors to meet the urgent need of patients by providing more affordable medicines.” – Langhua Pharma "Access is at the core of all work undertaken by the team at MPP. This has helped in close cooperation between pharma and generics and has ensured that newer and safer medicines reach people across LMICs." – Macleods "We at Mangalam Drugs & Organics Ltd. take great pride in being associated with MPP that is striving relentlessly to provide rapid access to effective healthcare across the globe. Having partnered with this organisation has enabled us to envision beyond the ordinary. We look forward to continued alliance with them and to be able to build on each other’s strengths for sustainable benefits to those who have limited reach." "At Micro Labs we duly appreciate the initiative taken by the team at MPP. MPP's efforts rightly opportune generic players to leverage their capabilities in reaching out to more patient population with quality and affordable medicines." "We believe the collaboration with MPP on expanding treatment access to affordable Hepatitis drugs has made a huge impact in many countries. It has been particularly satisfying to be part of the solution to tackle Hepatitis pandemic." – Natco "Our Stridian organizational values of Integrity, Collaboration and Efficiency resonate very well with those of the Medicines Patent Pool. Over the years, our partnership has promoted inclusivity, and worked towards making life-saving drugs affordable and accessible to large parts of the lower and middle income countries, thereby making a significant difference to public health.” – Strides Pharma "The partnership with MPP & its licensing model has enabled supply of critical life-saving medicines to patients in low- & middle-income countries around the world.” – Sun Pharma "Our association with MPP has strengthened our resolve in combating the scourge of hepatitis C. The inclusion of Daclatasvir to our anti-hep C portfolio has helped us extend Daclatasvir as a highly affordable treatment option to thousands of patients, suffering from hepatitis C, thereby improving both, their access to treatment and clinical outcomes." – Zydus Cadila Full list of first signatories of the open pledge: [lgc_column grid="30" tablet_grid="50" mobile_grid="100" last="false"] Adcock Ingram Arene Aurobindo Beximco Celltrion Desano Emcure Hetero Langhua Pharma Laurus Labs Lupin Macleods Mangalam Micro Labs Natco Strides Pharma Sun Pharma Zydus Cadila [/lgc_column] [lgc_column grid="70" tablet_grid="50" mobile_grid="100" last="false"] [/lgc_column] Contact: Gelise McCullough Head of Communications | Medicines Patent Pool +41 79 685 64 36 gmccullough@medicinespatentpool.org [post_title] => Leading Generic Drug Makers Unite to Pledge Capacity for Developing and Delivering Affordable COVID-19 Interventions as Pandemic Intensifies [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => covid-19-generic-pledge-press-release [to_ping] => [pinged] => [post_modified] => 2020-11-13 09:56:38 [post_modified_gmt] => 2020-11-13 09:56:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://medicinespatentpool.org/?post_type=news-publications&p=7715 [menu_order] => 150 [post_type] => news-publications [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [number_of_posts_to_show] => -1 [post_type] => news-publications [disease_styles] => [news_publication_type] => [people_type] => [company_type] => [story_type] => [include_filters] => [show_images] => 1 [show_events_from_date] => all ) [4] => Array ( [acf_fc_layout] => text_editor_block [text_editor] => Further info/clarifications: Gelise McCullough Head of Communications | Medicines Patent Pool +41 79 685 64 36 gmccullough@medicinespatentpool.org [text_editor_styles] => Array ( [alignment] => left [text_colour_font] => text-default [background_colour] => grey [background_image] => [background_image_style] => center / cover no-repeat [overlay_colour] => false ) ) )
In November 2020, a united group 18 companies representing a large portion of the world’s generic pharmaceutical manufacturers pledged to work together via the Medicines Patent Pool (MPP) to accelerate access to hundreds of millions of doses of new COVID-19 interventions for low- and middle-income countries (LMICs). Today, this number has grown to 25 and the open pledge continues to call on other leading players in the generic medicines landscape to join the generic manufacturers in this united effort and sign this pledge so that we can work shoulder to shoulder to end this pandemic.
As a united group of leading pharmaceutical manufacturing companies, suppliers and distributors from around the world providing treatments to millions, most of whom live in LMICs, we come together, through this signed pledge to support the fight against COVID-19. We affirm our joint engagement and offer our capacity to develop and supply COVID-19 treatments – re-purposed, new, small molecules and biologics – to those in need.
One thread that connects us, the signees of this pledge, is our commitment to the fight against COVID-19 and our willingness to work with the UN-backed MPP in ensuring that no one is left behind. MPP’s model, with its transparency, non-exclusivity and proven track record, has set the gold standard for public health voluntary licensing.
Access the press release
The task is mammoth, the demand is global. The collective gets stronger with each generic manufacturer, supplier and distributor joining the effort. To join the pledge and offer your production and/or supply capacity, click “Join the pledge” below.
JOIN THE PLEDGE
To show your support for the effort in ensuring that LMICs are not left behind as COVID-19 treatments become available, click “Support the pledge” below.
SUPPORT THE PLEDGE
Note: Joining or supporting the pledge is in no way legally binding. It simply affirms your intent and support in ensuring rapid access to treatments to those in need wherever they live in the world through the voluntary licensing mechanism of MPP.
“Working with MPP over the years has enabled Adcock Ingram to provide access to live saving medication to those in need in South Africa and its surrounds.”
“Associating with MPP has put us at the forefront of improving the accessibility and affordability of HIV medication. Our values and vision are closely aligned and they have continuously inspired us to do more for this cause.” – Arene Life Sciences
“We are committed to the cause of providing increased access to affordable high quality life saving medicines in low- and middle-income countries in several therapy areas including HIV. We have worked successfully with MPP over the years to this effect and will continue our fight through these valuable partnerships.” – Aurobindo
“MPP is committed to fighting health disparity through its unique strategy and we are proud to be a part of this network with the common goal of ensuring access to medicines for all.” – Beximco
“The very foundation of Cadila Pharmaceuticals is synonymous with quality and affordability of life-saving medicines. Our association with the MPP further strengthens our resolve to extend high-quality novel drugs to the last mile. Our expertise spans all major therapy areas and first-in-the-world innovations. Our immunomodulatory drug Sepsivac, used in gram negative sepsis, has been found to help in boosting innate immune response and has shown promising results in management of COVID 19 and also in increasing resistance against the development of COVID-19.”
“Medicines Patent Pool has led Paths of pharmaceutical products into People’s lives.” – Celltrion
“Our endeavour to ensure equitable access to quality and affordable healthcare is entrenched in our humanitarian purpose of ‘Caring for Life’ that has driven our efforts in India and globally over the past 85 years. Our partnership with MPP has helped us in providing access to life-saving drugs for HIV and other therapies.” – Cipla
“The capacity and capability of global leading generics pharmaceutical manufacturers have been better utilized with MPP’s coordination to make the life-saving HIV and hepatitis C medicines available and affordable in LMICs. We Desano feel proud to be part of this.”
“MPP make life-saving medicines in low- and middle-income countries affordable, we feel great honour to be a member of the team, contributing our capacity and delivery.” – Jiangxi Dongbang Pharmaceutical
“We believe that accelerating access to good health requires – developing medicines where affordable alternatives don’t exist, working with all stakeholders in the healthcare systems and ensuring adequate availability of medicines. Aligned with our belief, ‘Good Health Can’t Wait’, we are committed to addressing unmet patient needs along with MPP.” – Dr. Reddy’s
“We are privileged to have partnered with MPP for the past decade which has led to creating a larger access to life-saving medicines across the globe; not only with HIV but for other therapies as well.” – Hetero
“Our company mission is contributing to the healthcare by supporting the improvement of medicine availability and affordability. It is great to work with MPP and Licensors to meet the urgent need of patients by providing more affordable medicines.” – Langhua Pharma
“MPP is spearheading an initiative that is so imperative for the developing countries around the world to have access to affordable, lifesaving medicines. We acknowledge the sincere efforts of Medicines Patent Pool to work alongside generic manufacturers to accelerate the development of affordable medications to LMICs.” – Lupin
“Access is at the core of all work undertaken by the team at MPP. This has helped in close cooperation between pharma and generics and has ensured that newer and safer medicines reach people across LMICs.” – Macleods
“We at Mangalam Drugs & Organics Ltd. take great pride in being associated with MPP that is striving relentlessly to provide rapid access to effective healthcare across the globe. Having partnered with this organisation has enabled us to envision beyond the ordinary. We look forward to continued alliance with them and to be able to build on each other’s strengths for sustainable benefits to those who have limited reach.”
“At Micro Labs we duly appreciate the initiative taken by the team at MPP. MPP’s efforts rightly opportune generic players to leverage their capabilities in reaching out to more patient population with quality and affordable medicines.”
“We believe the collaboration with MPP on expanding treatment access to affordable Hepatitis drugs has made a huge impact in many countries. It has been particularly satisfying to be part of the solution to tackle Hepatitis pandemic.” – Natco
“Our Stridian organizational values of Integrity, Collaboration and Efficiency resonate very well with those of the Medicines Patent Pool. Over the years, our partnership has promoted inclusivity, and worked towards making life-saving drugs affordable and accessible to large parts of the lower and middle income countries, thereby making a significant difference to public health.” – Strides Pharma
“The partnership with MPP & its licensing model has enabled supply of critical life-saving medicines to patients in low- & middle-income countries around the world.” – Sun Pharma
“Our association with MPP has strengthened our resolve in combating the scourge of hepatitis C. The inclusion of Daclatasvir to our anti-hep C portfolio has helped us extend Daclatasvir as a highly affordable treatment option to thousands of patients, suffering from hepatitis C, thereby improving both, their access to treatment and clinical outcomes.” – Zydus Cadila
Gelise McCullough Head of Communications | Medicines Patent Pool +41 79 685 64 36 gmccullough@medicinespatentpool.org
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.